Supplementary Tables 1-5 from Preexisting MEK1<sup>P124</sup> Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
Dataset en
Authors
MC
Matteo S. Carlino
CF
Carina Fung
HS
Hamideh Shahheydari
Abstract
1 min read
<p>Supplementary Tables 1-5. S1 In silico evaluation of MEK1 Proline124 variants; S2 Correlation of factors and MEK1 mutation status; S3. Predictors of response to BRAF inhibition; S4. Univariate progression-free survival (PFS) according to MEK1 status; S5 Characterisation of melanoma cell Lines.</p>
Matteo S. Carlino, Carina Fung, Hamideh Shahheydari, Jason R. Todd, Suzanah C. Boyd, Mal Irvine, Adnan Nagrial, Richard A Scolyer, Richard F. Kefford, Georgina V. Long, Helen Rizos
Matteo S. Carlino, Carina Fung, Hamideh Shahheydari, Jason R. Todd, Suzanah C. Boyd, Mal Irvine, Adnan Nagrial, Richard A Scolyer, Richard F. Kefford, Georgina V. Long, Helen Rizos
Matteo S. Carlino, Carina Fung, Hamideh Shahheydari, Jason R. Todd, Suzanah C. Boyd, Mal Irvine, Adnan Nagrial, Richard A Scolyer, Richard F. Kefford, Georgina V. Long, Helen Rizos
Matteo S. Carlino, Carina Fung, Hamideh Shahheydari, Jason R. Todd, Suzanah C. Boyd, Mal Irvine, Adnan Nagrial, Richard A Scolyer, Richard F. Kefford, Georgina V. Long, Helen Rizos
Matteo S. Carlino, Carina Fung, Hamideh Shahheydari, Jason R. Todd, Suzanah C. Boyd, Mal Irvine, Adnan Nagrial, Richard A Scolyer, Richard F. Kefford, Georgina V. Long, Helen Rizos
Discussion(0)
No comments yet. Be the first to comment.